EPA:NANO - Euronext Paris - Matif - FR0011341205 - Common Stock - Currency: EUR
EPA:NANO (4/25/2025, 7:00:00 PM)
2.86
-0.04 (-1.55%)
The current stock price of NANO.PA is 2.86 EUR. In the past month the price decreased by -13.6%. In the past year, price decreased by -47.52%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
4AB.DE | ABBVIE INC | 17.83 | 285.16B | ||
1ABBV.MI | ABBVIE INC | 16.92 | 266.76B | ||
AMG.DE | AMGEN INC | 14.07 | 131.97B | ||
1GILD.MI | GILEAD SCIENCES INC | 22.33 | 112.99B | ||
GIS.DE | GILEAD SCIENCES INC | 13.26 | 112.70B | ||
VX1.DE | VERTEX PHARMACEUTICALS INC | 1657.31 | 110.78B | ||
ARGX.BR | ARGENX SE | 352.5 | 32.72B | ||
22UA.DE | BIONTECH SE-ADR | N/A | 24.54B | ||
IDP.DE | BIOGEN INC | 7.16 | 15.20B | ||
0QF.DE | MODERNA INC | N/A | 9.45B | ||
1MRNA.MI | MODERNA INC | N/A | 9.08B | ||
GLPG.AS | GALAPAGOS NV | N/A | 1.54B |
Nanobiotix SA is a late-stage biotechnology company, which engages in the development of therapeutic approaches to the treatment of cancer. The company is headquartered in Paris, Ile-De-France and currently employs 108 full-time employees. The company went IPO on 2012-10-29. The firm designs and manufactures nanoparticles that safely enhance the efficacy of radiation therapy in the treatment of cancer. The company develops new tools for cancer that utilize a physical mode of action at the cellular level of the cancer cell. The firm's NanoXray technology comprises three products. Local treatment (surgery and radiotherapy) provides potential cure and gives the systemic treatment a better chance to life expectancy. NanoXray products are developed for the efficacy of radiotherapy in the tumor cell. Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo.
NANOBIOTIX
60 rue de Wattignies
Paris ILE-DE-FRANCE FR
Employees: 110
Company Website: https://www.nanobiotix.com
Investor Relations: http://ir.nanobiotix.com
Phone: 33140260470
The current stock price of NANO.PA is 2.86 EUR. The price decreased by -1.55% in the last trading session.
The exchange symbol of NANOBIOTIX is NANO and it is listed on the Euronext Paris - Matif exchange.
NANO.PA stock is listed on the Euronext Paris - Matif exchange.
11 analysts have analysed NANO.PA and the average price target is 11.24 EUR. This implies a price increase of 292.9% is expected in the next year compared to the current price of 2.86. Check the NANOBIOTIX stock analysts ratings, price target forecast and up-and down grades for more detailed information.
NANOBIOTIX (NANO.PA) has a market capitalization of 135.58M EUR. This makes NANO.PA a Micro Cap stock.
NANOBIOTIX (NANO.PA) currently has 110 employees.
NANOBIOTIX (NANO.PA) has a resistance level at 3.01. Check the full technical report for a detailed analysis of NANO.PA support and resistance levels.
The Revenue of NANOBIOTIX (NANO.PA) is expected to decline by -3.32% in the next year. Check the estimates tab for more information on the NANO.PA EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
NANO.PA does not pay a dividend.
NANOBIOTIX (NANO.PA) will report earnings on 2025-05-20.
NANOBIOTIX (NANO.PA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.44).
ChartMill assigns a fundamental rating of 1 / 10 to NANO.PA. NANO.PA may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months NANO.PA reported a non-GAAP Earnings per Share(EPS) of -1.44. The EPS decreased by -33.33% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -101.06% | ||
ROE | N/A | ||
Debt/Equity | N/A |
ChartMill assigns a Buy % Consensus number of 85% to NANO.PA. The Buy consensus is the average rating of analysts ratings from 11 analysts.
For the next year, analysts expect an EPS growth of 33.28% and a revenue growth -3.32% for NANO.PA